Drug Profile
Research programme: chemokine receptor antagonists - Novartis
Alternative Names: CCR5 antagonists research programme - Novartis; Chemokine receptor antagonists research programme - Novartis; NIBR 1182; NIBR 1282; Research programme: CCR5 antagonists - NovartisLatest Information Update: 19 Jul 2010
Price :
$50
*
At a glance
- Originator Novartis
- Class
- Mechanism of Action CCR5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Transplant rejection
Most Recent Events
- 24 May 2004 Preclinical trials in Transplant rejection in Switzerland (unspecified route)